Wire · opportunities
Freenome SimpleScreen Blood-Based Colorectal Cancer Screening Test Gets FDA Approval
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 28 July 2026 · Fusion42 review
Freenome's SimpleScreen, a blood-based colorectal cancer screening test, has received FDA approval. The approval comes one week after the company's SPAC IPO.
This Wire brief sits within Fusion42's coverage of Diagnostics, and 4 sources have reported it between 27 Jul 2026 and 28 Jul 2026.
◆ ◆ The Wire takeaway
Freenome just cleared the regulatory gate for a non-invasive colorectal cancer screen. If you build supporting infrastructure—lab software, sample logistics, reporting platforms—a newly FDA-cleared test now needs to scale from lab to clinical adoption, and Freenome's public status means it has capital to build or buy integrations.
◆ Coverage
4 sources · first reported 27 Jul 2026 · latest 28 Jul 2026
◆ Related on Wire
◆ Topics